Association of sequence variations in vitamin K epoxide reductase and γ-glutamyl carboxylase genes with biochemical measures of vitamin K status

Journal of Nutritional Science and Vitaminology

Volumn 55, Issue 2, 2009, Pages 112-119

  Crosier, Michael D ^a   Peter, Inga ^b   Booth, Sarah L ^a   Bennett, Grace ^a   Dawson Hughes, Bess ^a   Ordovas, Jose M ^a  

^a TUFTS UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Gamma glutamyl carboxylase; Polymorphism; Vitamin K; Vitamin K epoxide reductase; Warfarin

Indexed keywords

ADENINE; BIOCHEMICAL MARKER; CARBOXYLASE; CYTOSINE; DECARBOXYPROTHROMBIN; GAMMA GLUTAMYL CARBOXYLASE; GUANINE; OSTEOCALCIN; OXIDOREDUCTASE; PHYTOMENADIONE; PLACEBO; PROTEIN INDUCED BY VITAMIN K ABSENCE FACTOR II; PROTHROMBIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K GROUP; BIOLOGICAL MARKER; GLUTAMYL CARBOXYLASE; LIGASE; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

AGED; AGING; ARTICLE; BIOCHEMICAL COMPOSITION; CARBOXYLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MALE; NUCLEOTIDE SEQUENCE; NUTRITIONAL STATUS; PROTEIN VARIANT; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN BLOOD LEVEL; VITAMIN K METABOLISM; VITAMIN SUPPLEMENTATION; BLOOD; GENETICS; HOMOZYGOTE; MIDDLE AGED; POSTMENOPAUSE;

AGED; BIOLOGICAL MARKERS; CARBON-CARBON LIGASES; FEMALE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NUTRITIONAL STATUS; OSTEOCALCIN; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; VITAMIN K 1;

EID: 67650757013     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.55.112     Document Type: Article

References (40)

1. Smith P, Arnesen H, Holme I. 1990. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323: 147-152. (Pubitemid 20219942)
2. Berkner KL. 2000. The vitamin K-dependent carboxylase. J Nutr 130: 1877-1880.
3. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT. 1998. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114: 445S-469S. (Pubitemid 28535775)
4. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. 2001. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin Pharmacol Ther 70: 159-164.
5. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, Wadelius C, Melhus H. 2004. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4: 40-48. (Pubitemid 38256604)
6. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. 2005. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 3: 137-145.
7. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333. (Pubitemid 41510803)
8. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E. 2006. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95: 205-211.
9. Michaud V, Vanier MC, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O'Hara G, Gossard D, Champagne M, Goodman K, Renaud Y, Brown A, Phillips M, Ajami AM, Turgeon J. 2008. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther 83: 740-748. (Pubitemid 351556023)
10. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S. 2005. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 77: 365-372. (Pubitemid 40719265)
11. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T. 2006. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120: 181-186. (Pubitemid 46754413)
12. Kohnke H, Sorlin K, Granath G, Wadelius M. 2005. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 61: 381-388. (Pubitemid 41569313)
13. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. 2006. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics 16: 609-611. (Pubitemid 44100205)
14. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. 2005. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5: 262-270. (Pubitemid 41131718)
15. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K. 2004. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103: 2630-2635. (Pubitemid 38393017)
16. Ferland G. 1998. The vitamin K-dependent proteins: an update. Nutr Rev 56: 223-230.
17. Presnell SR, Stafford DW. 2002. The vitamin K-dependent carboxylase. Thromb Haemost 87: 937-946.
18. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352: 2285-2293.
19. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J. 2005. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94: 773-779. (Pubitemid 41489236)
20. Gundberg CM, Nieman SD, Abrams S, Rosen H. 1998. Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab 83: 3258-3266. (Pubitemid 28500970)
21. Booth SL, Dallal G, Shea MK, Gundberg CG, Peterson J, Dawson-Hughes B. 2008 Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 93: 1217-1223.
22. McKeown NM, Jacques PF, Gundberg CM, Peterson JW, Tucker KL, Kiel DP, Wilson PWF, Booth SL. 2002. Dietary and non-dietary determinants of vitamin K biochemical measures in men and women. J Nutr 132: 1329-1334.
23. Davidson KW, Sadowski JA. 1997. Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol 282: 408-421.
24. Sadowski JA, Hood SJ, Dallal GE, Garry PJ. 1989. Phylloquinone in plasma from elderly and young adults: factors influencing its concentration. Am J Clin Nutr 50: 100-108.
25. Erkkila AT, Lichtenstein AH, Dolnikowski GG, Grusak MA, Jalbert SM, Aquino KA, Peterson JW, Booth SL. 2004. Plasma transport of vitamin K in men using deuterium- labeled collard greens. Metabolism 53: 215-221.
26. Kohlmeier M, Salomon A, Saupe J, Shearer MJ. 1996. Transport of vitamin K to bone in humans. J Nutr 126: 1192S-1196S.
27. McNamara JR, Schaefer EJ. 1987. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 166: 1-8.
28. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4: 357-362.
29. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. 2004. Identification of the gene for vitamin K epoxide reductase. Nature 427: 541-544. (Pubitemid 38209111)
30. Kuo WL, Stafford DW, Cruces J, Gray J, Solera J. 1995. Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12. Genomics 25: 746-748.
31. Lewontin RC. 1964. The interaction of selection and linkage. Optimum models. Genetics 50: 757-782.
32. Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, D'Agostino RB Sr, Ordovas JM, O'Donnell CJ, Dawson- Hughes B, Vasan RS, Booth SL. 2007. Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr (Epub ahead of print).
33. Jin DY, Tie JK, Stafford DW. 2007. The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry 46: 7279-7283.
34. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105: 645-649. (Pubitemid 40070748)
35. de Boer-van den Berg MA, Thijssen HH, Vermeer C. 1986. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat. Biochim Biophys Acta 884: 150-157. (Pubitemid 16007961)
36. Sokoll LJ, Sadowski JA. 1996. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr 63: 566-573.
37. Comings DE, MacMurray JP. 2000. Molecular heterosis: a review. Mol Genet Metab 71: 19-31.
38. Population Estimates for Counties by Age Group: July 1, 1999.
39. Ioannidis JP, Ntzani EE, Trikalinos TA. 2004. 'Racial' differences in genetic effects for complex diseases. Nat Genet 36: 1312-1318. (Pubitemid 39577941)
40. Goldstein DB, Hirschhorn JN. 2004. In genetic control of disease, does 'race' matter? Nat Genet 36: 1243-1244.